JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB257250

Human ARID1A knockout HEK-293T cell lysate

Be the first to review this product! Submit a review

|

(1 Publication)

ARID1A KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 11 bp deletion in exon1.
2 Images
Sanger Sequencing - Human ARID1A knockout HEK-293T cell lysate (AB257250)
  • Sanger seq

Unknown

Sanger Sequencing - Human ARID1A knockout HEK-293T cell lysate (AB257250)

Homozygous : 11 bp deletion in exon1

Western blot - Human ARID1A knockout HEK-293T cell lysate (AB257250)
  • WB

Lab

Western blot - Human ARID1A knockout HEK-293T cell lysate (AB257250)

Lanes 1 - 3 : Merged signal (red and green). Green - ab182560 observed at 270 kDa. Red - loading control ab8245 (Mouse anti-GAPDH antibody [6C5]) observed at 37 kDa.

ab182560 was shown to react with ARID1A in wild-type HEK-293T cells in Western blot with loss of signal observed in ARID1A knockout cell line ab266189 (ARID1A knockout cell lysate ab257250). Wild-type HEK-293T and ARID1A knockout cell lysates were subjected to SDS-PAGE. Membranes were blocked in 3 % milk in TBS-T (0.1 % Tween®) before incubation with ab182560 and ab8245 (Mouse anti-GAPDH antibody [6C5]) overnight at 4°C at a 1 in 1000 dilution and a 1 in 20000 dilution respectively. Blots were incubated with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 h at room temperature before imaging.

All lanes:

Western blot - Anti-ARID1A antibody [EPR13501] (<a href='/en-us/products/primary-antibodies/arid1a-antibody-epr13501-ab182560'>ab182560</a>) at 1/1000 dilution

Lane 1:

Wild-type HEK-293T cell lysate at 20 µg

Lane 2:

Western blot - Human ARID1A knockout HEK-293T cell lysate (ab257250) at 20 µg

Lane 3:

SH-SY5Y cell lysate at 20 µg

Secondary

Lanes 1 - 3:

Western blot - Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-irdye-800cw-preadsorbed-ab216773'>ab216773</a>) at 1/20000 dilution

Lanes 1 - 3:

Western blot - Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (<a href='/en-us/products/secondary-antibodies/goat-mouse-igg-h-l-irdye-680rd-preadsorbed-ab216776'>ab216776</a>) at 1/20000 dilution

Predicted band size: 242 kDa

Observed band size: 270 kDa

false

Key facts

Cell type

HEK-293T

Species or organism

Human

Tissue

Kidney

Knockout validation

Sanger Sequencing,Western blot

Mutation description

Knockout achieved by using CRISPR/Cas9, 11 bp deletion in exon1.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "Sanger seq": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" }, "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Product details

Knockout cell lysate achieved by CRISPR/Cas9.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1Kit": { "sellingSize": "1 Kit", "publicAssetCode":"ab257250-1Kit", "assetComponentDetails": [ { "size":"1 x 100 µg", "name":"Human ARID1A knockout HEK293T cell lysate", "number":"AB257250-CMP01", "productcode":"" }, { "size":"1 x 100 µg", "name":"Human wild-type HEK293T cell lysate", "number":"AB257250-CMP02", "productcode":"" } ] } } }

Properties and storage information

Gene name
ARID1A
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing, Western blot
Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

ARID1A also known as BAF250A is a protein encoded by the ARID1A gene and forms part of the SWI/SNF chromatin remodeling complex. The molecular weight of ARID1A is approximately 270 kDa. This protein is expressed in many tissues but higher expression is noted in the liver kidney and placenta. ARID1A contains an ARID (A-T Rich Interaction Domain) which allows it to bind DNA influencing transcription regulation significantly.
Biological function summary

ARID1A impacts cellular functions through its role in the SWI/SNF complex. This complex modulates chromatin structure and is integral to DNA accessibility which in turn controls gene expression. ARID1A's involvement helps in regulating transcription factors and affects processes such as cell growth and differentiation. Its function is necessary for maintaining proper cell proliferation and apoptosis balance.

Pathways

ARID1A plays a central role in transcriptional regulation and cell cycle control. It shows interaction with the tumor suppressor protein p53 and is implicated in the PI3K/AKT signaling pathway. ARID1A's function in these pathways affects cellular responses to DNA damage and growth signals linking it closely to important cellular fate decisions.

Mutations or loss of function in ARID1A has been strongly associated with various cancers including ovarian and endometrial cancers. In these contexts ARID1A dysfunction often occurs alongside other proteins such as p53 contributing to tumorigenesis by deregulating tumor suppressive pathways. It also holds a potential connection to neurodevelopmental disorders due to its role in chromatin remodeling and gene expression.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Publications (1)

Recent publications for all applications. Explore the full list and refine your search

Cancers 15: PubMed37627124

2023

Development of an Enzyme-Linked Immunosorbent Assay (ELISA) for the Quantification of ARID1A in Tissue Lysates.

Applications

Unspecified application

Species

Unspecified reactive species

Manuel Hinsberger,Julia Becker-Kettern,Wiebke M Jürgens-Wemheuer,Joachim Oertel,Walter J Schulz-Schaeffer
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com